Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Candesartan cilexetil
Drug ID BADD_D00347
Description Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00796
KEGG ID D00626
MeSH ID C077793
PubChem ID 2540
TTD Drug ID Not Available
NDC Product Code 62559-641; 70771-1207; 17228-0032; 0378-3224; 46708-341; 62559-642; 63629-2126; 62332-341; 62332-342; 68382-191; 68382-193; 70771-1205; 52562-100; 46708-342; 0378-3232; 70771-1206; 46708-060; 46708-343; 60687-119; 60687-130; 62332-343; 17228-0016; 64220-114; 49884-659; 68382-190; 17228-0017; 65372-1128; 49884-658; 63629-2127; 68382-192; 70518-2719; 70518-2884; 60687-241; 62332-060; 62559-643; 0378-3225; 70771-1204; 17228-0018; 72761-002; 49884-661; 62559-640; 0378-3231; 49884-660
UNII R85M2X0D68
Synonyms candesartan cilexetil | 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate | 1H-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- | Parapres | Kenzen | Amias | Blopress | Atacand | TCV 116 | TCV-116
Chemical Information
Molecular Formula C33H34N6O6
CAS Registry Number 145040-37-5
SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC 6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.001262%
Chronic kidney disease20.01.03.0170.001682%
Bone marrow failure01.03.03.005--
Nephritic syndrome20.05.01.0060.001682%Not Available
Adverse reaction08.06.01.0180.001262%Not Available
Low birth weight baby18.04.02.0030.000841%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000841%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.002103%
Acute kidney injury20.01.03.0160.021867%
Foetal growth restriction18.03.01.0020.001262%
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.000841%Not Available
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.002523%Not Available
Diffuse alopecia23.02.02.0070.001682%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000841%
Cornea verticillata06.06.03.0160.002103%Not Available
Bladder transitional cell carcinoma16.08.01.002; 20.03.04.0030.000841%Not Available
Dermatitis exfoliative generalised23.03.07.002; 10.01.01.0290.000841%Not Available
Open angle glaucoma06.03.01.0040.000841%Not Available
Small for dates baby18.04.02.0020.001682%Not Available
Right ventricular dysfunction02.04.02.0330.000841%
Left atrial dilatation02.04.02.0250.001262%Not Available
Facial asymmetry15.10.05.0040.000841%Not Available
Exposed bone in jaw15.02.04.0340.000841%Not Available
Tendon discomfort15.07.01.0120.001262%Not Available
Fine motor skill dysfunction17.01.02.0200.000841%Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.035--Not Available
Atypical haemolytic uraemic syndrome20.01.03.027; 17.02.10.027; 07.11.01.032; 01.06.02.0030.000841%Not Available
Bladder transitional cell carcinoma recurrent20.03.04.012; 16.08.01.0080.000841%Not Available
Blood loss anaemia24.07.01.088; 01.03.02.0180.000841%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.001682%Not Available
The 15th Page    First    Pre   15 16    Next   Last    Total 16 Pages